Gastroschisis Outcomes of Delivery (GOOD) Study

H
Hiba Mustafa, MD

Primary Investigator

Enrolling By Invitation
18 years and older
Female
Phase 3
800 participants needed
1 Location

Brief description of study

The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectantgement with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we willdomized, prospective, multi-institutional trial across NAFTNet-affiliatedutions. Patients may be enrolled in the study any time prior to 33 weeks, but will bedomized at 33 weeks to delivery at 35 weeks or observation with a goal of 38 weeks. They composite outcome will include stillbirth, neonatal death prior to discharge,y morbidity, and need for parenteral nutrition at 30 days.

Detailed description of study

Gastroschisis is the most common congenital abdominal wall abnormality in which theutside of body floating in the amniotic fluid. This is diagnosed by prenatal ultrasound at 18-20 weeks gestation. Gastroschisis occurs in 1 out of every 4000 births andhe incidence is increasing. The majority of patients with gastroschisis have an uncomplicated neonatal course and recover well after surgical repair. However, subsets of gastroschisis patients have more complicated courses due to loss of intestine or blockages ofhe intestine These infants have a higher risk of death and long-term morbidity. Additionally, gastroschisis patients have an increased risk of in-utero fetal demise orbirth.
The potential risk of pregnancy loss late in the third trimester has prompted some physiciansdeliver gastroschisis patients prior to term. This results in an increased chance ofdditional prematurity-related complications. There is no consensus about the ideal time to deliver a baby with gastroschisis and practice patterns vary widely. It is unclear whichhe fetus a chance at a better outcome: early delivery to mitigate risk of stillbirthd intestinal injury versus delivery closer to term.
Retrospective data published show inconsistent results on outcomes with early delivery orgestational age delivery in gastroschisis. There have been two randomized, prospectivewith delivery early versus awaiting spontaneous labor. The first included 42 patientsdering the study largely underpowered. There was a trend towards decreased length of hospital stay and earlier time to full enteral feeding in the early delivery group, but this did not reach statistical significance. The latest study was stopped early because ofutility and an increased risk of sepsis in the early group. There was no increase in sepsishe early group in the first trial, and the study design of this trial varies greatly from both studies.
Standard delivery times for uncomplicated gastroschisis are between 34 and 39 weeks gestation. As the current available literature does not adequately answer the question ofgestational age of delivery in patients with gastroschisis, the objective of thisudy is to investigate the hypothesis that delivery at 35 0/7 - 35 6/7 weeks in stablewith gastroschisis is superior to observation and expectant management with a goaldelivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a randomized,ve, multi-institutional trial. Patients may be enrolled in the study any time prior33 weeks but will be randomized at 33 weeks to delivery at 35 weeks or observation with a goal of 38 weeks. The primary outcome will be based on a weighted composite comprised ofuterine fetal demise, neonatal/infant death prior to discharge, respiratory morbidity, gastrointestinal morbidity, and sepsis. We will compare the rates of the composite outcome as well as the individual components to determine whether a significant difference between thewo strategies can be detected. Secondary maternal outcomes include need for labor induction,d for cesarean section, and complications of delivery including infection, bloodusions, and thromboembolic events. We will also evaluate antenatal test values, such asuid index, estimated fetal weight, and intra- and extra-abdominal bowel dilation.dary neonatal outcomes include birth and discharge weight, central venous catheter days,zing enterocolitis, time to enteral autonomy, individualy morbidity, need for caffeine, and length of stay.
Given the unprecedented patient data being collected for the randomized trial, we plan toverage the infrastructure built for this study to generate the largest prospective,ulticenter database of gastroschisis-related (maternal, fetal, and neonatal) outcomes in thed States. The database will provide data for future development of both hypotheses andudy design regarding gastroschisis-related outcomes. The associated biobank will collect blood from the neonatal participants to be stored and analyzed in future research.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Gastroschisis
  • Age: 18 Years
  • Gender: Female

Inclusion criteria:
To be eligible for study inclusion, subjects are required to meet the following criteria:
  1. Speak English or Spanish
  2. Age of ≥18 years old
  3. Have a diagnosis of an isolated fetal gastroschisis confirmed via sonogram at ≤33weeks gestation
  4. Have a singleton pregnancy
  5. Capable of providing written informed consent for study participation
  6. Established Estimated Date of Confinement (EDC) prior to 22 0/7 weeks GA by lastual period (LMP) with ultrasound confirmation or ultrasound dating when LMP isunknown.
Exclusion criteria:
Subjects will be excluded from enrollment for any of the following criteria
  1. Fetal anomaly unrelated to gastroschisis, such as a chromosomal abnormality or anothergenital structural abnormality (if known; no additional testing required forh participation)
  2. Severe intrauterine growth restriction / fetal growth restriction (defined as growthbelow the 5th percentile for gestational age)
  3. Maternal history of previous stillbirth (intrauterine fetal demise)
  4. Maternal history of spontaneous preterm (<36 weeks) delivery
  5. Maternal cervical length < 25 mm prior to 24 weeks of gestation if documented
  6. Maternal hypertension
  7. Maternal insulin-dependent diabetes
  8. Prenatal care initiated after 24 weeks of gestation
  9. An active case of COVID-19 (confirmed by a positive test for COVID-19) that is notvered (confirmed by a negative test for COVID-19) by the date of randomization
  10. Unstable pregnancy defined as meeting any of the following criteria
    1. Abnormal amniotic fluid volume defined as oligohydramnios or polyhydramnios wherehe maximal vertical pocket (MVP) is < 2 cm or > 8 cm in the third trimester,vely
    2. Umbilical artery Dopplers with S/D ratio or resistive index (RI) > 97thge with or without absent or reversed end diastolic flow
    3. Non-stress test (NST) or biophysical profile (BPP) deemed non-reassuring byg clinician
  11. Concurrent enrollment in another study that requires either a treatment or
    intervention which would either alter the delivery plan or potentially influence thed neonatal outcomes of this study
  12. Traditional surrogacy, gestational surrogacy, gestational carrier, or gestationalurrogate
  13. Incapable of providing informed consent
  14. Are not their own legally authorized representative.

Updated on 01 Aug 2024. Study ID: 898740-1
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center